Haemonetics Co. (NYSE:HAE) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Haemonetics Co. (NYSE:HAE - Get Free Report) have been assigned an average rating of "Moderate Buy" from the nine analysts that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $108.78.

A number of equities research analysts have commented on the stock. Raymond James upgraded shares of Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 price target for the company in a report on Friday, November 8th. Barrington Research reissued an "outperform" rating and set a $108.00 target price on shares of Haemonetics in a research report on Wednesday, December 4th. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a report on Friday, December 6th. They set an "overweight" rating and a $116.00 price target on the stock. Finally, Needham & Company LLC reiterated a "buy" rating and set a $112.00 price target on shares of Haemonetics in a report on Tuesday, December 3rd.

Institutional Investors Weigh In On Haemonetics

A number of hedge funds have recently modified their holdings of HAE. Commonwealth Equity Services LLC grew its holdings in Haemonetics by 3.3% during the second quarter. Commonwealth Equity Services LLC now owns 3,673 shares of the medical instruments supplier's stock valued at $304,000 after purchasing an additional 117 shares during the period. Vontobel Holding Ltd. raised its stake in Haemonetics by 3.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 4,878 shares of the medical instruments supplier's stock valued at $392,000 after purchasing an additional 180 shares during the period. Keene & Associates Inc. lifted its stake in Haemonetics by 3.0% in the 3rd quarter. Keene & Associates Inc. now owns 10,174 shares of the medical instruments supplier's stock worth $818,000 after purchasing an additional 298 shares in the last quarter. Versor Investments LP boosted its holdings in shares of Haemonetics by 9.1% during the 3rd quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier's stock valued at $289,000 after purchasing an additional 300 shares during the last quarter. Finally, First Personal Financial Services grew its position in shares of Haemonetics by 2.9% during the third quarter. First Personal Financial Services now owns 11,110 shares of the medical instruments supplier's stock valued at $893,000 after purchasing an additional 312 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Haemonetics Stock Up 0.6 %

Shares of HAE opened at $79.91 on Wednesday. Haemonetics has a 52 week low of $70.25 and a 52 week high of $97.97. The firm has a market cap of $4.01 billion, a P/E ratio of 33.16, a price-to-earnings-growth ratio of 1.26 and a beta of 0.41. The firm's 50-day simple moving average is $82.67 and its 200 day simple moving average is $80.43. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.09 by $0.03. The firm had revenue of $345.50 million during the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The business's revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.99 EPS. On average, analysts forecast that Haemonetics will post 4.59 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.